Potential of Immunoglobulin A to Prevent Allergic Asthma

Allergic asthma is characterized by bronchial hyperresponsiveness, a defective barrier function, and eosinophilic lower airway inflammation in response to allergens. The inflammation is dominated by Th2 cells and IgE molecules and supplemented with Th17 cells in severe asthma. In contrast, in health...

Full description

Bibliographic Details
Main Authors: Gloudemans, Anouk K., Lambrecht, Bart N., Smits, Hermelijn H.
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649226/
id pubmed-3649226
recordtype oai_dc
spelling pubmed-36492262013-05-20 Potential of Immunoglobulin A to Prevent Allergic Asthma Gloudemans, Anouk K. Lambrecht, Bart N. Smits, Hermelijn H. Review Article Allergic asthma is characterized by bronchial hyperresponsiveness, a defective barrier function, and eosinophilic lower airway inflammation in response to allergens. The inflammation is dominated by Th2 cells and IgE molecules and supplemented with Th17 cells in severe asthma. In contrast, in healthy individuals, allergen-specific IgA and IgG4 molecules are found but no IgE, and their T cells fail to proliferate in response to allergens, probably because of the development of regulatory processes that actively suppress responses to allergens. The presence of allergen-specific secretory IgA has drawn little attention so far, although a few epidemiological studies point at a reverse association between IgA levels and the incidence of allergic airway disease. This review highlights the latest literature on the role of mucosal IgA in protection against allergic airway disease, the mechanisms described to induce secretory IgA, and the role of (mucosal) dendritic cells in this process. Finally, we discuss how this information can be used to translate into the development of new therapies for allergic diseases based on, or supplemented with, IgA boosting strategies. Hindawi Publishing Corporation 2013 2013-04-11 /pmc/articles/PMC3649226/ /pubmed/23690823 http://dx.doi.org/10.1155/2013/542091 Text en Copyright © 2013 Anouk K. Gloudemans et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Gloudemans, Anouk K.
Lambrecht, Bart N.
Smits, Hermelijn H.
spellingShingle Gloudemans, Anouk K.
Lambrecht, Bart N.
Smits, Hermelijn H.
Potential of Immunoglobulin A to Prevent Allergic Asthma
author_facet Gloudemans, Anouk K.
Lambrecht, Bart N.
Smits, Hermelijn H.
author_sort Gloudemans, Anouk K.
title Potential of Immunoglobulin A to Prevent Allergic Asthma
title_short Potential of Immunoglobulin A to Prevent Allergic Asthma
title_full Potential of Immunoglobulin A to Prevent Allergic Asthma
title_fullStr Potential of Immunoglobulin A to Prevent Allergic Asthma
title_full_unstemmed Potential of Immunoglobulin A to Prevent Allergic Asthma
title_sort potential of immunoglobulin a to prevent allergic asthma
description Allergic asthma is characterized by bronchial hyperresponsiveness, a defective barrier function, and eosinophilic lower airway inflammation in response to allergens. The inflammation is dominated by Th2 cells and IgE molecules and supplemented with Th17 cells in severe asthma. In contrast, in healthy individuals, allergen-specific IgA and IgG4 molecules are found but no IgE, and their T cells fail to proliferate in response to allergens, probably because of the development of regulatory processes that actively suppress responses to allergens. The presence of allergen-specific secretory IgA has drawn little attention so far, although a few epidemiological studies point at a reverse association between IgA levels and the incidence of allergic airway disease. This review highlights the latest literature on the role of mucosal IgA in protection against allergic airway disease, the mechanisms described to induce secretory IgA, and the role of (mucosal) dendritic cells in this process. Finally, we discuss how this information can be used to translate into the development of new therapies for allergic diseases based on, or supplemented with, IgA boosting strategies.
publisher Hindawi Publishing Corporation
publishDate 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649226/
_version_ 1611976404518305792